Reporting to the Translational Medicine Senior Scientist I, this individual will serve as an integral team member with exposure to multiple facets of business operations. The Research Associate will be responsible for conducting immunogenicity assays to measure efficacy of clinical vaccines and work closely with the Translational Medicine team. Additional features of the position include responsibility for performing mouse experiments to characterize the immune response to vaccine candidates.
Elicio (ELTX) is a growing organization based out of the Seaport area of Boston, Massachusetts with additional staff functioning in a virtual based environment from the Greater Boston area and throughout the United States.
Major Duties/Responsibilities

• Execute immunogenicity and/or biomarkers assays such as ELISPOT/Fluorospot, ELISA, ICS and other flow cytometry-based assays
• Assist with optimization and development of novel in vitro T cell and antibody-based assays
• Tissue culture of primary human immune cells
• Perform testing of clinical samples following appropriate SOPs, completing all necessary documentation and analyzing data
• Perform PBMC isolations from whole blood and leukopak for research and clinical studies
• Responsible for sample management including receiving and shipping clinical samples and maintaining sample chain of custody
• Perform murine handling, injections, and blood/organ collections
• Willingness to learn new analytical assays
• Ability to work independently and interact collaboratively with other team members
• Perform job responsibilities in compliance with GCLP, where applicable

Education & Professional Experience
Required:

• BS with 1-5 years of relevant work experience OR MS with 0-3 years of experience
• Local to Boston or willing to relocate
• Ability to start immediately
• US Citizen (not able to sponsor for this position)

Skills:

• Aseptic technique
• Detail oriented
• Effective written and oral communication
• Overall collaborative nature and willingness to learn in a dynamic environment
• Experience with flow cytometry and T cell based assays a plus

Working Conditions
Busy office/laboratory environment with frequent deadlines and interruptions
Travel: Travel is not required
Physical Requirements: Subject to periods of sitting or standing, vision is required to monitor data.
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the Amphiphile ("AMP") technology, which allows for therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system's cancer-fighting capabilities. By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes' natural ability to educate, activate and amplify cancer-specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. The Company's R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations, respectively). For more information, please visit www.elicio.com.
About the Amphiphile Platform
Elicio Therapeutics' proprietary Amphiphile ("AMP") platform delivers investigational immunotherapeutics directly to the "brain center" of the immune system - the lymph nodes. Elicio believes this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators may efficiently educate, activate, and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, Elicio has observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio believes our AMP lymph node-targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based upon preclinical studies. Elicio's AMP platform, originally developed at the Massachusetts Institute of Technology has broad potential in the cancer space to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships. The AMP platform has been shown to deliver immunotherapeutics directly to the lymph nodes by latching on to the protein albumin, found in the bloodstream, as it travels to lymphatic tissue. In preclinical models, Elicio has observed lymph node-specific engagement driving immune responses of increased magnitude, function and durability.